Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jun 10 04:00PM ET
4.55
Dollar change
+0.07
Percentage change
1.56
%
IndexRUT P/E- EPS (ttm)-0.30 Insider Own7.84% Shs Outstand156.01M Perf Week-2.15%
Market Cap728.71M Forward P/E44.75 EPS next Y0.10 Insider Trans-0.32% Shs Float147.60M Perf Month-9.18%
Income-45.08M PEG- EPS next Q-0.03 Inst Own54.43% Short Float11.92% Perf Quarter3.64%
Sales222.55M P/S3.27 EPS this Y77.03% Inst Trans32.24% Short Ratio5.93 Perf Half Y21.98%
Book/sh-0.23 P/B- EPS next Y219.61% ROA-13.83% Short Interest17.60M Perf Year92.80%
Cash/sh0.36 P/C12.47 EPS next 5Y- ROE-617.16% 52W Range2.03 - 6.07 Perf YTD34.22%
Dividend Est.- P/FCF- EPS past 5Y40.01% ROIC-20.91% 52W High-25.04% Beta0.72
Dividend TTM- Quick Ratio1.17 Sales past 5Y136.89% Gross Margin77.34% 52W Low124.14% ATR (14)0.25
Dividend Ex-Date- Current Ratio1.72 EPS Y/Y TTM35.11% Oper. Margin-10.11% RSI (14)46.00 Volatility2.08% 3.36%
Employees394 Debt/Eq- Sales Y/Y TTM29.88% Profit Margin-20.25% Recom1.33 Target Price6.58
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q55.22% Payout- Rel Volume0.58 Prev Close4.48
Sales Surprise0.32% EPS Surprise-21.21% Sales Q/Q47.94% EarningsMay 08 BMO Avg Volume2.97M Price4.55
SMA20-4.79% SMA50-1.20% SMA20021.59% Trades Volume1,953,405 Change1.56%
Date Action Analyst Rating Change Price Target Change
Nov-11-24Downgrade Piper Sandler Overweight → Neutral $3
Mar-28-24Initiated Oppenheimer Outperform $5
Aug-28-23Initiated Craig Hallum Buy $4.50
Oct-21-22Initiated Jefferies Buy $4
Apr-28-22Initiated Craig Hallum Buy $6.50
Nov-17-21Initiated SVB Leerink Outperform $6
Oct-29-21Initiated H.C. Wainwright Buy $4
Apr-07-21Resumed RBC Capital Mkts Outperform $11
Feb-18-20Initiated Piper Sandler Overweight $12
Jul-16-18Initiated RBC Capital Mkts Outperform $24
Jun-03-25 07:30AM
May-20-25 07:30AM
May-12-25 03:54PM
May-09-25 03:21AM
May-08-25 08:20AM
07:17AM
07:00AM
May-07-25 12:08PM
11:51AM
May-05-25 05:30PM
May-01-25 07:00AM
Apr-22-25 06:46PM
Apr-17-25 07:00AM
Mar-28-25 08:00AM
Mar-27-25 10:18AM
Mar-20-25 10:13AM
Mar-19-25 04:49PM
Mar-17-25 08:00AM
Mar-07-25 02:08AM
Mar-06-25 09:30AM
08:15AM
07:22AM
07:00AM
Feb-27-25 07:00AM
Feb-26-25 10:00AM
Feb-24-25 08:00AM
Feb-05-25 08:00AM
Jan-21-25 09:00AM
Jan-11-25 07:27AM
Jan-10-25 07:00AM
Jan-06-25 04:15PM
Nov-26-24 07:00AM
Nov-09-24 02:06AM
Nov-08-24 09:30AM
08:10AM
07:10AM
07:00AM
Oct-31-24 08:00AM
Oct-04-24 04:05PM
Aug-22-24 07:00AM
Aug-08-24 08:25AM
07:30AM
07:00AM
Aug-01-24 10:01AM
Jul-25-24 07:00AM
Jul-24-24 09:55AM
Jul-08-24 07:00AM
Jul-03-24 01:05PM
Jun-03-24 07:00AM
May-30-24 07:30AM
07:00AM
May-10-24 03:21PM
12:36PM
12:27AM
May-09-24 11:55AM
08:10AM
07:11AM
07:00AM
May-06-24 07:42AM
07:00AM
May-02-24 07:00AM
Apr-03-24 04:05PM
Apr-02-24 07:00AM
Mar-07-24 01:47PM
11:56AM
Mar-06-24 11:16PM
12:52PM
08:15AM
07:17AM
07:02AM
07:00AM
Mar-05-24 09:42AM
Feb-28-24 07:00AM
Feb-05-24 07:00AM
Jan-11-24 08:30AM
Jan-10-24 08:00AM
Jan-08-24 02:48PM
Jan-05-24 04:05PM
Jan-04-24 07:00AM
Dec-27-23 07:00AM
Dec-23-23 07:32PM
Dec-20-23 02:00PM
Nov-17-23 01:07PM
Nov-10-23 04:00PM
01:53AM
Nov-09-23 11:30AM
08:10AM
07:17AM
07:00AM
Oct-26-23 06:15PM
Oct-16-23 07:00AM
Sep-27-23 08:00AM
Sep-20-23 07:36AM
Sep-14-23 04:05PM
Aug-28-23 07:00AM
Aug-17-23 11:00AM
Aug-11-23 09:09AM
Aug-10-23 11:59AM
Aug-08-23 12:05PM
09:15AM
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fairley Ricki LouiseDirectorMay 09 '25Proposed Sale4.9056,667277,668May 09 05:28 PM
Hecht BethSee RemarksMar 20 '25Sale5.4340,000217,2441,353,510Mar 21 05:31 PM
Hecht BethOfficerMar 20 '25Proposed Sale5.1440,000205,600Mar 20 05:26 PM
Pieper StevenSee RemarksNov 22 '24Option Exercise1.5519,48330,1991,441,820Nov 26 05:00 PM
Schmid John P.DirectorAug 12 '24Buy2.254,51510,14725,200Aug 13 04:15 PM
Schmid John P.DirectorAug 09 '24Buy2.374,28510,13420,685Aug 12 06:28 PM
OSZAR »